Skadden is representing Otsuka Holdings Co., Ltd. in the approximately $1.1 billion acquisition by its subsidiary Otsuka Pharmaceutical Co., Ltd. of Jnana Therapeutics Inc. The deal includes an upfront payment of $800 million and up to $325 million contingent upon development and regulatory milestones.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates